Closed-System Drug Transfer Devices Evaluated in Study – APhA submits compounding comments to FDA. – (866) 348-2889.
Amid concern over test protocols for closed-system drug transfer devices (CSTDs), an independent study has examined the effectiveness of various CSTD models.1
CSTDs, when designed and used appropriately, offer enhanced protection against potentially hazardous exposures to health care workers during the compounding and administration of hazardous drugs.2
The study, conducted by researchers at the Centre Hospitalier Régional in France, first performed a total of 21 usability tests on 7 CSTDs: ChemoClave, ChemoLock, Equashield, Phaseal, Qimono, Tevadaptor, and Viashield.1